Serum hyaluronan is increased in malignant lymphoma

Area of Science:

• Biochemistry
• Oncology
• Immunology

Background:

• Malignant lymphoma is a significant hematologic malignancy.
• Hyaluronan (HYA) is a key component of the extracellular matrix with roles in cell signaling and tissue hydration.
• Alterations in HYA metabolism have been implicated in various diseases.

Purpose of the Study:

• To investigate serum hyaluronan (HYA) concentrations in patients with malignant lymphoma.
• To compare HYA levels between lymphoma subtypes (Hodgkin's disease and non-Hodgkin's lymphoma) and disease stages.
• To explore the relationship between serum HYA levels and disease activity.

Main Methods:

• Serum samples were collected from 41 patients diagnosed with malignant lymphoma.
• Hyaluronan (HYA) concentrations were quantified using established laboratory assays.
• Patients were staged according to conventional procedures, and disease status (diagnosis, relapsed/resistant) was recorded.

Main Results:

• Median serum HYA concentration was significantly higher in lymphoma patients (40.7 ng/ml) compared to healthy controls (14.5 ng/ml) (P = 0.00032).
• Patients with relapsing or resistant disease, particularly those in stages III and IV, exhibited the highest HYA levels (median 181.5 ng/ml).
• Untreated patients showed moderately elevated HYA levels (median 29.8 ng/ml) compared to controls.

Conclusions:

• Elevated serum hyaluronan (HYA) is a potential biomarker for malignant lymphoma.
• Increased HYA levels correlate with disease burden and activity, suggesting a role in lymphoma pathogenesis.
• Malignant transformation of lymphatic tissue may lead to decreased HYA uptake and degradation.